initi neutral rate pt
eloxx develop treatment diseas caus nonsens
mutat result stop codon prevent normal
translat protein eloxx platform reli eukaryot
ribosom select glycosid ersg compound mediat ribosom
activ allow read nonsens mutat therebi
restor translat result product full length function
protein initi eloxx develop treatment cystic fibrosi
cf cystinosi diseas target eloxx
lead investig drug complet subject
healthi volunt phase sad trial current complet
cf per protocol dose-find studi cf patient
conduct belgium expect initi
addit per manag phase studi cystinosi
initi us hesit around compani cf
program drive decis initi coverag neutral rate
price target
eloxx believ better read-through agent
ataluren march rate
announc ataluren confirmatori phase trial act cf
nonsens mutat achiev either primari secondari
endpoint program discontinu lead hypothesi
propos regard variabl previou ataluren studi
aminoglycosid tobramycin bind compet ataluren
ribosom site thu yield poor respons cf patient
background tobramycin eloxx believ compar ataluren
better read-through agent select
cytoplasm site vs mitochondri site may therefor
enhanc activ belief select allow less
competit tobramycin greater eukaryot vs prokaryot
select thu ensur higher avail drug level infect cf
airway shown vitro activ three tradit use
stop codon demonstr improv toxicolog profil
limit seriou kidney hear loss concern stabil rna
prevent assembl nonsense-medi decay factor
requir initi decay mrna
continu next page
definit distribut analyst rate analyst certif disclosur pleas refer page report
howev less convinc believ eloxx invest well sar chemistri gener molecul
appear significantli improv properti could support read-through harbor number concern
surround cf data gener compani date organoid swell assay valuabl assay determin
particular genotyp respond particular therapi opinion lack rigor quantifi magnitud
respons moreov swell assay specif cftr activ simpli measur increas fluid respons
depend mani differ variabl cftr express correspond uss chamber
measur correl activ uss chamber assay gold standard preclin assay valid
cftr activ eloxx manag refer experi induc wild type cftr activ
del hbe cell awar eloxx poster european cystic fibrosi north american cystic
fibrosi confer present hbe uss measur discuss thought experi
within bodi report although manag report mrna express level treat organoid
measur cftr protein western blot analysi wide accept mrna protein express
level well correl separ measur perform gen cf
kol state lack corrobor data asid organoid data limit confid approach
atalauren trial consist show oppos result base geographi trial site-loc initi trial conduct israel
appear posit could never replic us sad trial perform israel mad
trial conduct israel belgium secondli phase trial cf subject conduct sole belgium
primari outcom sweat chlorid swcl concern issu plagu may occur
eloxx whether investig error mere differ patient popul
eloxx also purs second indic cystinosi cystinosi rare metabol disord result
accumul dimer form cystein cystin cystin transport lysosom via protein
cystinosin cytoplasm degrad prior excret mutat within cystinosin gene result
defect transport retent cystin crystal kidney eye liver muscl pancrea brain white blood cell
untreat children cystinosi develop end stage kidney failur age nine preclin model
shown reduc cystin accumul encourag mrna level elev treatment
howev opinion lack dose respons somewhat confus taken context previou
experi cf organoid differ could account appar dose respons organoid model system
present furthermor differ import enough may effect potenti outcom clinic trial
valuat risk invest thesi price target base equally-weight composit
multipl tax dilut ep discount back line
expect pe multipl discount rate earli development-stag biotechnolog compani npv
share discount cash flow analysi use discount rate growth rate line expect discount
growth paramet earli development-stag biotechnolog compani risk invest thesi target price
includ achiev signific outcom clinic studi abl secur regulatori approv
us eu success achiev peak commerci revenu estim model due market size
compani overview catalyst
develop treatment diseas caus nonsens mutat result stop
codon prevent normal translat protein eloxx platform reli eukaryot ribosom select
glycosid ersg compound mediat ribosom activ allow read nonsens mutat
therebi restor translat result product full length function protein initi eloxx develop
treatment cystic fibrosi cf cystinosi diseas target eloxx lead
investig drug complet subject healthi volunt phase sad trial
current complet phase mad trial healthi volunt per protocol propos phase trial cf
dose-find studi cf patient conduct belgium expect initi
per manag phase trial cystinosi initi us
figur import compani event horizon
cf trial initi
trial initi
 wainwright research compani report
approv therapi cftr nonsens mutat
figur avail therapi cf patient
current class nonsens stop mutat patient compris remain cf popul
lack approv therapi correct basic defect cftr
littl histori lesson ataluren investig fail
read-through therapi class cf patient
aminoglycosid induc conform chang within ribosom allow codon-anticodon
mismatch therebi allow read-through prematur termin codon use howev limit
less ideal safeti profil includ kidney toxic possibl hear loss
principl read-through well-develop shown effect indic
 ataluren develop approv eu treatment nonsens mutat patient
mechan action ataluren well develop numer report confirm activ
vitro pna
work develop ataluren read-through agent class cf patient well
trial howev consist variabl controversi respect outcom includ question
regard geograph trial differ use inhal antibiot potenti toxic
march compani announc ataluren confirmatori phase trial act cf
nonsens mutat achiev either primari secondari endpoint program
lead hypothesi propos regard variabl previou ataluren studi
aminoglycosid tobramycin novarti nv rate bind compet ataluren
ribosom site thu cf patient tobi inhal formul tobramycin observ posit
effect ataluren antimicrob agent chemoth
compar aminoglycosid gentamycin ataluren opinion
select cytoplasm site vs mitochondri site may therefor enhanc
activ select also allow less competit tobramycin
greater eukaryot vs prokaryot select thu ensur higher avail drug level
shown vitro activ three tradit use stop codon
demonstr improv toxicolog profil limit seriou kidney hear loss concern
stabil ribosom rna prevent assembl nonsense-medi decay factor
requir initi decay mrna
fare better ataluren cf class mutat
organoid swell assay valuabl assay determin particular genotyp respond
particular therapi opinion lack rigor quantifi magnitud respons moreov
swell assay specif cftr activ simpli measur increas fluid respons
depend mani differ variabl cftr express
correspond uss chamber measur correl activ uss
chamber assay gold standard preclin assay valid cftr activ eloxx present data
show induc wild type cftr activ hbe cell awar
eloxx poster confer eloxx present hbe
uss measur opinion studi lack suffici detail adequ interpret
provid thought data later document
although manag report mrna express level treat organoid
measur cftr protein western blot analysi wide accept mrna protein express
level well correl separ measur perform gen
cf kol state lack confid data thu far organoid data
well corrobor extens uss measur western blot protein measur
atalauren trial consist show oppos result base geographi trial site-loc initi trial
conduct israel appear posit could never replic us sad trial
perform israel mad trial conduct israel belgium secondli phase
trial cf subject conduct sole belgium primari outcom sweat chlorid swcl
concern issu plagu may occur eloxx whether investig
error mere differ patient popul
figur eloxx scaffold gener greater read-
cf mutat either gentamycin
demonstr read-through activ
mutat
efficaci shown significantli greater
gentamycin
opinion eloxx invest well sar chemistri gener molecul appear
significantli improv properti could support read-through level higher observ
earlier molecul gentamycin believ may due abil stabil
ribosom rna prevent assembl nonsense-medi decay factor would otherwis
initi mrna decay opinion abl demonstr stabl mrna product vivo may
provid opportun function greater level ataluren
may improv safeti profil
compar ataluren
toxicolog studi perform rat show expect safeti margin start
dose mad studi start dose test phase
base preclin data eloxx anticip efficaci clinic dose
provid fold margin no-observed-adverse-effect-level noael rat sensit
furthermor alreadi complet healthi volunt sad phase trial per protocol
cohort identifi receiv dose rang sae report
consid safe well-toler dose
opinion signific sar work led develop molecul gener higher
level read-through although yet clear level high enough improv safeti profil
margin may prevent kidney hear loss side effect may abl stabil
ribosom suffici nonsense-medi decay molecul initi ribosom
therefor suffici level mrna transcrib
stimul swell organoid effect
poc use quantit measur
figur organoid demonstr swell treatment
stimul swell organoid increas dose demonstr increas cumul
believ organoid swell may use indic efficaci mani variabl definit
character respons entir due cftr although applaud effort quantifi auc still
concern measur difficult verifi rate fluid accumul satur
possibl higher level read-through function cftr may translat thu rate fluid
swell may faster organoid could satur sooner howev scenario believ min
auc level would longer due initi linear kinet opinion rate swell measur initi
kinet reliabl way quantifi respons even measur initi kinet believ
one unequivoc determin rate swell due cftr express
modul depend mutat
organoid deriv homozygot
modul alon potenti corrector
combin
opinion seri experi
present conundrum organoid swell
experi top panel clear
effect stimul swell
organoid modul
stimul activ middl panel
modul essenti compar elx-
modul suggest addit
thu effect lower panel
gener
unfortun tripl combin
perform
definit
ascrib current mediat entir
cftr
difficulti
appear
show dose respons
organoid swell mrna express
figur effect homozyg organoid
previous discuss concern regard attempt quantifi organoid swell repeat
opinion nanostr mrna assay may import piec data eloxx present
demonstr sustain mrna express impli may inhibit nonsens mediat decay
stabil ribosom rna prevent assembl nonsense-medi decay factor requir initi
decay mrna opinion may singl greatest advantag
previou agent ataluren ensur mrna gener via read-through
protect nonsense-medi decay although posit still confirm increas level cftr
protein mention mrna protein level typic well correl
demonstr increas cftr current
hbe cell
eloxx present data oral session european cystic fibrosi confer ecf belgrad
serbia dr row univers alabama birmingham show stimul chlorid
secret fischer rat thyroid cell level stimul stimul chlorid
secret bronchial epitheli hbe cell control level
demonstr level activ presenc absenc tobramycin cy fib
opinion data set mix posit outcom lack tobramycin effect neg
outcom compar effect cell fold increas compar neglig
activ hbe cell
sinc tobramycin shown inhibit ataluren activ half maxim inhibitori concentr
pna novemb demonstr effect sinc
one major hypothes ataluren work believ outcom may support
effect
view surpris gener cftr current compar
cell preclin data read-through provid figur suggest perform
better seen previous mani differ scenario often hard translat result
cell-fre system cell base assay yet alon vivo outcom
likewis view data hbe cell modest improv cftr read-through opinion
improv greater compar wild-typ cftr may requir ensur translat
observ effect clinic trial
eloxx design phase studi evalu
cf patient
phase trial conduct belgium expect enrol patient least one
allel per protocol accord compani present trial ascend dose trial
use sweat chlorid outcom per manag top-line data expect
surpris choic swcl primari outcom phase trial follow
reason regul choic approv endpoint cf modul trial swcl
correl well previou vertex buy rate run modul trial level correct
gener compar swcl improv higher level achiev see vertex tripl
correl appear reliabl effect swcl may reflect increas uptak
sweat gland appar coordin uptak airway ataluren show effect
swcl improv match improv phase trial ultim fail
achiev improv phase
due varieti unansw question regard preclin data well uncertainti respect
phase trial design outcom measur choos adopt cautiou approach wait
clinic proof efficaci valid abil mediat read-through cf class mutat
assumpt class cf mutat
model us commerci launch cf
regard us cf market assum approxim patient annual growth
translat popul
model cf popul class mutat
model peak penetr cf class patient choos peak
penetr due lack competitor agent class cf patient
current assum launch annual cost per patient
assign probabl success combin clinic regulatori adjust
revenu project accordingli choos po due improv efficaci demonstr preclin
model enhanc abil prevent nonsense-medi decay
assum eu us revenu adjust factor base eu cf preval treatment
penetr eu annual cost
taken collect assumpt yield probabl adjust world-wide revenu cf eloxx
grow
cff registri data wainwright calcul
cystinosi second target indic eloxx
cystinosi rare metabol disord result accumul dimer form cystein
 cystin cystin transport lysosom via protein cystinosin cytoplasm
degrad prior excret mutat within cystinosin gene result defect transport
retent cystin crystal kidney eye liver muscl pancrea brain white blood cell
untreat children cystinosi develop end stage kidney failur age nine
common nonsens mutat caus cystinosi account approxim
patient cystinosi genet
treatment involv liber fluid salt replac reduc cystin level extrem case
cysteamin fda-approv cystine-deplet agent may use cysteamin proven effect
delay prevent renal failur oral kidney liquid suspens optic
accord cystinosi research foundat approxim individu cystinosi
us ww
reduc cystin accumul preclin model
figur show mrna stabil reduct cystin
abl show increas level mrna left panel abl decreas cystin
level either mous fibroblast middl panel mous kidney cell sub-cutan deliveri right
encourag mrna level elev treatment howev
opinion lack dose respons somewhat confus taken context previou
experi cf organoid differ could account appar dose respons
organoid model system present furthermor differ import enough may
effect potenti outcom clinic trial
eloxx file ind cystinosi us anticip phase trial initi
evalu patient chang cystein level measur white blood cell
assumpt cystinosi
model us commerci launch cystinosi
regard us cystinosi market assum approxim patient annual growth
translat popul
model cystinosi popul nonsens stop mutat elig
patient rise patient
model peak penetr elig choos peak penetr due
ultra rare natur cystinosi anticip difficulti identifi elig patient translat
treat
current assum launch annual cost per patient
assign probabl success combin clinic regulatori adjust
revenu project accordingli choos po due demonstr sustain messag
level reduct cystin level murin kidney cell
assum eu us revenu adjust factor base eu cystinosi preval treatment
penetr eu annual cost
taken collect assumpt yield probabl adjust world-wide revenu cystinosi
eloxx grow
cystinosi research foundat wainwright calcul
valuat invest risk
valuat method price target base equally-weight composit
multipl tax dilut ep discount back line
expect pe multipl discount rate earli development-stag biotechnolog compani npv
discount cash flow analysi use discount rate growth rate line
expect discount growth paramet earli development-stag biotechnolog compani
risk invest thesi target price
regulatori risk due except clinic outcom high patient physician demand eloxx
pharmaceut could receiv expedit regulatori approv product develop
would pose risk neutral rate yet also regulatori risk might
receiv regulatori approv product develop regulatori approv may
delay applic submit addit healthcar reform countri may impact
commerci risk eloxx could success market sell pipelin product
receiv regulatori approv current compani market product could rapidli
build access sale market medic liaison team well establish distribut infrastructur
addit demand could great unmet need physician accept drug
govern payor reimburs could expect potenti government price
control would pose risk neutral rate may need build sale market medic
liaison team well establish distribut infrastructur risk includ physician accept drug
govern payor reimburs line expect potenti government price control
clinic develop risk eloxx current investig sever asset clinic trial
enrol mayb rapid expect high demand within patient popul result
rapid complet clinic trial addit clinic trial outcom may robust demonstr high level
statist clinic signific well excel safeti profil would pose risk neutral
rate altern enrol may take signific amount time clinic trial trial may postpon
delay varieti reason addit outcom trial difficult predict could fail
number reason includ safeti efficaci
manufactur risk eloxx oper manufactur facil eloxx may rapidli negoti
third-parti contract manufactur execut mutual benefici agreement commerci product
manufactur capac demand other may easili address within manufactur
agreement ensur ampl suppli develop commerci eloxx could maintain
excel timelin cost structur well maintain abil manufactur consist product
convers manufactur capac demand other expect increas develop
commerci eloxx could face issu time cost present risk well abil
manufactur consist product manufactur facil highli regul subject risk closur
financi risk eloxx incur oper loss sinc incept view may achiev
profit sever year compani could need rais capit futur sustain oper
addit stock biotechnolog compani like publicli trade compani subject market volatil
liquid risk small trade float
liabil risk eloxx product candid could gener excel safeti profil undesir side
effect condit may affect subject trial commerci patient compani
issu product liabil lawsuit may occur compani may issu regard typic busi
liabil downsid eloxx product candid may caus undesir side effect
properti could result legal action taken subject trial commerci patient
compani product liabil lawsuit common biopharmaceut industri compani also
vulner typic busi liabil associ conduct busi litigi environ
intellectu properti risk eloxx reli patent trade secret protect product competit
biotechnolog industri litigi lawsuit consid normal part busi eloxx
intellectu properti right might excel suscept possibl litig furthermor
may appar eloxx develop entir process infring
upon properti right hand court might uphold eloxx intellectu properti right
though far could find eloxx infring upon anoth parti properti right addit
biotech firm could potenti find loophol eloxx intellectu properti estat might enabl
launch gener version eloxx product prior expir patent protect product
eloxx unabl obtain protect intellectu properti right may abl compet effect
commerci market
except per share valu
revenu
revenu
revenu
expens net
except patient number
revenu cf probabl adjust
revenu cystinosi probabl adjust
us revenu cf
class patient
patient
probabl success
us revenu cf probabl adjust
eu revenu cf
us cf pt
us treatmen penetr
us treament annual cost
eu revenu cf probabl adjust
us revenu cystinosi
non-stop mutat
patient
probabl success
us revenu cystinosi probabl adjust
eu revenu cystinosi
us cystinosi pt
us treatmen penetr
us treament annual cost
eu revenu cystinosi probabl adjust
mm except per share valu
cash equival
prepaid current asset
equip furnitur fixtur net
acquir research develop
total liabil stockhold equiti
warrant stock right liabil
seri prefer stock
common stock treasuri cost
discount
sensit ep estim
discount
chang work capit
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc elox-u
rate price target histori inc vrtx-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl decemb
 wainwright co llc firm member finra sipc regist broker-deal
andrew fein li wang watsek alicia yin ph certifi view express report accur
reflect person view subject secur issuer discuss part compens
directli indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur eloxx
pharmaceut inc includ without limit option right warrant futur long short posit
novemb neither firm affili benefici class common equiti secur
inc
neither research analyst firm materi conflict interest research analyst know
reason know time public research report
research analyst firm and/or research analyst household financi interest secur
includ without limit option right warrant futur long short posit
novemb neither firm affili benefici class common equiti secur
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc inc
invest bank servic within twelv month seek compens compani mention
report invest bank servic within three month follow public research report
firm make market inc inc date research
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
